
























REIVINDICACIONES

1. Un compuesto que es:

No.	Estructura	No.	Estructura
1		109B	
1A			
1B			
2			
3			
4			
5		113	










No.	Estructura	No.	Estructura
6		114A	
7		114B	
7A			
7B		116	
8			
9		118A	
10		118B	










No.	Estructura	No.	Estructura
11			
11A			
11B			
12			
12A			
12B			
13			
14			









No.	Estructura	No.	Estructura
15			
16			
17			
18			
19			
20			

No.	Estructura	No.	Estructura
21		129A	
22		129B	
23			
24		131A	
25		131B	
26			
27			
28			












No.	Estructura	No.	Estructura
29			
30			
31			
32			
33			
34			
35		141A	
36		141B	









No.	Estructura	No.	Estructura
37			
38A			
38B			
39			
40			
41			
42		147	
43			

No.	Estructura	No.	Estructura
43A			
44			
45			
46			
46A			
46B			
47			
48		154A	

No.	Estructura	No.	Estructura
49		154B	
50			
50A	 Primer isómero eluyente		
50B	 Segundo isómero eluyente		
51			
52			
53			









No.	Estructura	No.	Estructura
55			
56			
58		163	
59		164	
60			
60A			
60B			
61			

No.	Estructura	No.	Estructura
		169	
		170A	
64		170B	
65			
67A		173	
67B		174	
68A		175	






No.	Estructura	No.	Estructura
68B		176	
69A			
69B			
70A			
70B			
71A			
71B			

No.	Estructura	No.	Estructura
72			
		181A	
		181B	
		183A	
78		183B	
79			
		185	

No.	Estructura	No.	Estructura
83A			
83B			
84		193	
87			
88			
89A			
89B			


No.	Estructura	No.	Estructura
90A		200	
90B			
		205	
		206	
		207	
		210	
		211	









No.	Estructura	No.	Estructura
		212	
101A		214	
101B			
		216	
103A			
103B			
104A		220	
104B			









No.	Estructura	No.	Estructura
105A			
105B			
		224	
		225	
109A			








o una sal, profármaco, tautómero, estereoisómero o mezcla de estereoisómeros farmacéuticamente aceptables de los mismos.









2. Un compuesto que es:
















































Primer isómero eluyente


















Segundo isómero eluyente



























o



o una sal, profármaco, tautómero, estereoisómero o mezcla de estereoisómeros farmacéuticamente aceptables de los mismos.

3. El compuesto de la reivindicación 2, en donde el compuesto es:



o un estereoisómero o una mezcla de estereoisómeros de los mismos, o una sal farmacéuticamente aceptable de los mismos.

4. Una composición farmacéutica que comprende un compuesto, o un estereoisómero o una mezcla de estereoisómeros, o una sal farmacéuticamente aceptable del mismo, de las reivindicaciones 1-3 y un excipiente.
5. Un método *in vitro* para inhibir la proteína quinasa 1 que interactúa con el receptor, que comprende poner en contacto una proteína quinasa 1 que interactúa con el receptor con un compuesto, o un estereoisómero o una mezcla de estereoisómeros, o una sal farmacéuticamente aceptable del mismo, de acuerdo con una cualquiera de las reivindicaciones 1-3 o la composición farmacéutica de la reivindicación 4.